Corey M McCann M.D., Ph.D. is the Founder, President, and Chief Executive Officer of Pear Therapeutics, an eHealth company developing drug/software combination products for diseases of the brain. Previously, he was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic investment partners, and oversaw strategy and execution at portfolio companies.
Prior to joining MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s central nervous system (CNS) expertise group, advising clients across the healthcare value chain.
Corey has previous investment experience with RiverVest Venture Partners, where he was an Associate performing diligence on early stage investments, and at NeuroInsights, where he was an Analyst evaluating brain related technologies. He is also founding member of Alcyone Lifesciences, a start-up developing technologies to deliver therapeutics to the brain.
In addition to the above, Corey has been an advisory board member or Board Director at multiple healthcare companies including Dragonfly Sciences, Selexys Pharmaceuticals, Companion PBx, AgNovos Healthcare, Edumedics, and ArthroMeda. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program.
For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis.
He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.